CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT01924260
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:33.214517+00:00
- Published At
- 2022-08-02T00:00:00+00:00
- Record Updated At
- 2022-08-02
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Acinar Cell Adenocarcinoma of the Pancreas", "Duct Cell Adenocarcinoma of the Pancreas", "Recurrent Pancreatic Cancer", "Stage III Pancreatic Cancer", "Stage IV Pancreatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2022-08-02"- protocolSection.identificationModule.nctId
"NCT01924260"- protocolSection.identificationModule.officialTitle
"Phase I Study of the Combination of MLN8237 and Gemcitabine in Advanced Solid Tumors With Emphasis on Pancreatic Cancer"- protocolSection.statusModule.overallStatus
"COMPLETED"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.